Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Diamyd Medical AB's Debt-to-EBITDA or its related term are showing as below:
FRA:DMN's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.15 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Diamyd Medical AB Debt-to-EBITDA Related Terms
Diamyd Medical AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMN vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (May. 2026) EBITDA data.
Diamyd Medical AB (FRA:DMN) has a Debt-to-EBITDA of 0.00 as of May. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Diamyd Medical AB. According to the industry distribution chart, Diamyd Medical AB ranks #999999 out of 296 companies in the Biotechnology industry.
Is Diamyd Medical AB's Debt-to-EBITDA too high?
Diamyd Medical AB's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Diamyd Medical AB ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #999999 out of 296 companies for Debt-to-EBITDA. This places Diamyd Medical AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Diamyd Medical AB. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Debt-to-EBITDA is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued.
The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Diamyd Medical AB to be Fairly Valued.
Key valuation signals for FRA:DMN:
Debt-to-EBITDA: 0.00
GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for FRA:DMN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMN has been successfully added to your 
